Chengdu Olymvax Biopharmaceuticals Inc. engages in the research and development, production, and sales of vaccines for human use in China. The company offers absorbed tetanus vaccine, group a and group c products; and haemophilus influenzae type b. It also provides Hib conjugate vaccine and AC conjugate vaccine; and group A and C meningococcal polysaccharide conjugate vaccine. The company was founded in 2009 and is based in Chengdu, China.

Sector

Healthcare

Industry

Biotechnology

CEO

Fan, Shaowen

Employees

470

Website

www.olymvax.com

IPO Date

2021-06-08

Headquarters

No. 99 Tianxin Road, High-tech Zone, Chengdu, Sichuan Province, 611731, China

Socials

NEWSLETTER

View Data Providers

NEWSLETTER

View Data Providers

Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.

Chengdu Olymvax Biopharmaceuticals 688319

Chengdu Olymvax Biopharmaceuticals Earnings Call Summary

Chengdu Olymvax Biopharmaceuticals Earnings

Transcripts

Events

About Chengdu Olymvax Biopharmaceuticals Inc.

Chengdu Olymvax Biopharmaceuticals
688319